Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel Maintenance in mCRPC Post-Docetaxel
NCT01707966Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Sep 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orteronel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Swiss Group for Clinical Cancer Research. Started Sep 2012; status: completed.
02
Drugs
orteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01707966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01707966.